Compile Data Set for Download or QSAR
Report error Found 165 Enz. Inhib. hit(s) with all data for entry = 7816
TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220380(US9290488, ZA01)
Affinity DataKi:  0.220nM ΔG°:  -55.1kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220382(US9290488, ZA03)
Affinity DataKi:  0.340nM ΔG°:  -54.0kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220363(US9290488, B20a(i))
Affinity DataKi:  0.890nM ΔG°:  -51.7kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220366(US9290488, B34a)
Affinity DataKi:  1.03nM ΔG°:  -51.3kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220366(US9290488, B34a)
Affinity DataEC50:  1.24nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220379(US9290488, L29b)
Affinity DataKi:  1.32nM ΔG°:  -50.7kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220375(US9290488, K2b(ii))
Affinity DataKi:  1.46nM ΔG°:  -50.4kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220384(US9290488, ZA05)
Affinity DataKi:  1.97nM ΔG°:  -49.7kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220383(US9290488, ZA04)
Affinity DataKi:  1.98nM ΔG°:  -49.7kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220385(US9290488, ZA06)
Affinity DataKi:  1.98nM ΔG°:  -49.7kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220362(US9290488, B12a)
Affinity DataKi:  2.21nM ΔG°:  -49.4kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220363(US9290488, B20a(i))
Affinity DataEC50:  2.62nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220376(US9290488, K29b)
Affinity DataKi:  2.64nM ΔG°:  -49.0kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220377(US9290488, L2b(i))
Affinity DataKi:  3.07nM ΔG°:  -48.6kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220381(US9290488, ZA02)
Affinity DataKi:  3.14nM ΔG°:  -48.5kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220386(US9290488, ZA07)
Affinity DataKi:  3.56nM ΔG°:  -48.2kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220378(US9290488, L2b(ii))
Affinity DataKi:  3.78nM ΔG°:  -48.1kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220379(US9290488, L29b)
Affinity DataEC50:  4.20nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220373(US9290488, E54a)
Affinity DataKi:  5.46nM ΔG°:  -47.2kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220383(US9290488, ZA04)
Affinity DataEC50:  5.84nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220361(US9290488, B11a(ii))
Affinity DataEC50:  6.54nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220376(US9290488, K29b)
Affinity DataEC50:  7.24nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220384(US9290488, ZA05)
Affinity DataKi:  7.40nM ΔG°:  -46.4kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220364(US9290488, B20a(ii))
Affinity DataKi:  7.44nM ΔG°:  -46.4kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220365(US9290488, B21a)
Affinity DataEC50:  7.80nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220362(US9290488, B12a)
Affinity DataEC50:  8.14nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220365(US9290488, B21a)
Affinity DataKi:  8.22nM ΔG°:  -46.1kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220360(US9290488, B11a(i))
Affinity DataKi:  9.80nM ΔG°:  -45.7kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220374(US9290488, H3a)
Affinity DataKi:  9.93nM ΔG°:  -45.7kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220383(US9290488, ZA04)
Affinity DataKi:  11.6nM ΔG°:  -45.3kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220387(US9290488, ZA08)
Affinity DataKi:  11.9nM ΔG°:  -45.2kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220388(US9290488, ZA09)
Affinity DataKi:  11.9nM ΔG°:  -45.2kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220378(US9290488, L2b(ii))
Affinity DataEC50:  12nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220361(US9290488, B11a(ii))
Affinity DataKi:  12.1nM ΔG°:  -45.2kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220375(US9290488, K2b(ii))
Affinity DataEC50:  14.3nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220377(US9290488, L2b(i))
Affinity DataEC50:  14.6nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220392(US9290488, CC02)
Affinity DataKi:  15nM ΔG°:  -44.7kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220360(US9290488, B11a(i))
Affinity DataEC50:  16.2nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220357(US9290488, A11a(ii))
Affinity DataKi:  19.2nM ΔG°:  -44.0kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220373(US9290488, E54a)
Affinity DataEC50:  21.7nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220386(US9290488, ZA07)
Affinity DataEC50:  22.9nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220389(US9290488, ZA10)
Affinity DataKi:  23nM ΔG°:  -43.6kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220372(US9290488, E53a(ii))
Affinity DataKi:  23.6nM ΔG°:  -43.5kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220381(US9290488, ZA02)
Affinity DataEC50:  24.2nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220384(US9290488, ZA05)
Affinity DataEC50:  24.5nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220359(US9290488, B2a(ii))
Affinity DataKi:  27.1nM ΔG°:  -43.2kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220362(US9290488, B12a)
Affinity DataKi:  29.1nM ΔG°:  -43.0kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220387(US9290488, ZA08)
Affinity DataEC50:  29.3nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220391(US9290488, CC01)
Affinity DataKi:  38nM ΔG°:  -42.4kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220363(US9290488, B20a(i))
Affinity DataKi:  38.9nM ΔG°:  -42.3kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

Displayed 1 to 50 (of 165 total ) | Next | Last >>
Jump to: